Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data

Keitaro Shimozaki; Yasutaka Sukawa; Yasunori Sato; Sara Horie; Akihiko Chida; Kai Tsugaru; Kazuhiro Togasaki; Kenta Kawasaki; Kenro Hirata; Hideyuki Hayashi; Yasuo Hamamoto; Takanori Kanai

doi:10.2217/fon-2020-0861

Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data

Keitaro Shimozaki, Yasutaka Sukawa, Yasunori Sato, Sara Horie, Akihiko Chida, Kai Tsugaru, Kazuhiro Togasaki, Kenta Kawasaki, Kenro Hirata, Hideyuki Hayashi, Yasuo Hamamoto, Takanori Kanai

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

The aim of this study was to determine the risk factors for immune-related adverse events (irAEs) induced by immune checkpoint inhibitors. The authors conducted a retrospective study in which patients with malignant melanoma, non-small-cell lung cancer, gastric cancer or renal cell carcinoma who received anti-PD-1/PD-L1 antibodies were included. Of 247 patients, 118 developed a total of 182 irAEs. In the multivariate Fine-Gray regression analysis, serum albumin level ≥3.6 g/dl (hazard ratio: 1.62; 95% CI: 1.10-2.39; p = 0.015) and history of Type I hypersensitivity reactions (hazard ratio: 1.48; 95% CI: 1.02-2.14; p = 0.037) were significantly associated with the development of irAEs. High serum albumin levels and history of Type I hypersensitivity reactions are risk factors for irAEs.

Original language	English
Pages (from-to)	2593-2603
Number of pages	11
Journal	Future Oncology
Volume	17
Issue number	20
DOIs	https://doi.org/10.2217/fon-2020-0861
Publication status	Published - 2021 Jul

Keywords

Fine-Gray regression model
PD-1
Type I hypersensitivity reaction
immune checkpoint inhibitors
immune-related adverse events
risk factor

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2217/fon-2020-0861

Cite this

@article{25435f12fa094ce1ba1dbd7474ecea83,

title = "Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data",

abstract = "The aim of this study was to determine the risk factors for immune-related adverse events (irAEs) induced by immune checkpoint inhibitors. The authors conducted a retrospective study in which patients with malignant melanoma, non-small-cell lung cancer, gastric cancer or renal cell carcinoma who received anti-PD-1/PD-L1 antibodies were included. Of 247 patients, 118 developed a total of 182 irAEs. In the multivariate Fine-Gray regression analysis, serum albumin level ≥3.6 g/dl (hazard ratio: 1.62; 95% CI: 1.10-2.39; p = 0.015) and history of Type I hypersensitivity reactions (hazard ratio: 1.48; 95% CI: 1.02-2.14; p = 0.037) were significantly associated with the development of irAEs. High serum albumin levels and history of Type I hypersensitivity reactions are risk factors for irAEs.",

keywords = "Fine-Gray regression model, PD-1, Type I hypersensitivity reaction, immune checkpoint inhibitors, immune-related adverse events, risk factor",

author = "Keitaro Shimozaki and Yasutaka Sukawa and Yasunori Sato and Sara Horie and Akihiko Chida and Kai Tsugaru and Kazuhiro Togasaki and Kenta Kawasaki and Kenro Hirata and Hideyuki Hayashi and Yasuo Hamamoto and Takanori Kanai",

year = "2021",

month = jul,

doi = "10.2217/fon-2020-0861",

language = "English",

volume = "17",

pages = "2593--2603",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "20",

}

TY - JOUR

T1 - Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data

AU - Shimozaki, Keitaro

AU - Sukawa, Yasutaka

AU - Sato, Yasunori

AU - Horie, Sara

AU - Chida, Akihiko

AU - Tsugaru, Kai

AU - Togasaki, Kazuhiro

AU - Kawasaki, Kenta

AU - Hirata, Kenro

AU - Hayashi, Hideyuki

AU - Hamamoto, Yasuo

AU - Kanai, Takanori

PY - 2021/7

Y1 - 2021/7

N2 - The aim of this study was to determine the risk factors for immune-related adverse events (irAEs) induced by immune checkpoint inhibitors. The authors conducted a retrospective study in which patients with malignant melanoma, non-small-cell lung cancer, gastric cancer or renal cell carcinoma who received anti-PD-1/PD-L1 antibodies were included. Of 247 patients, 118 developed a total of 182 irAEs. In the multivariate Fine-Gray regression analysis, serum albumin level ≥3.6 g/dl (hazard ratio: 1.62; 95% CI: 1.10-2.39; p = 0.015) and history of Type I hypersensitivity reactions (hazard ratio: 1.48; 95% CI: 1.02-2.14; p = 0.037) were significantly associated with the development of irAEs. High serum albumin levels and history of Type I hypersensitivity reactions are risk factors for irAEs.

AB - The aim of this study was to determine the risk factors for immune-related adverse events (irAEs) induced by immune checkpoint inhibitors. The authors conducted a retrospective study in which patients with malignant melanoma, non-small-cell lung cancer, gastric cancer or renal cell carcinoma who received anti-PD-1/PD-L1 antibodies were included. Of 247 patients, 118 developed a total of 182 irAEs. In the multivariate Fine-Gray regression analysis, serum albumin level ≥3.6 g/dl (hazard ratio: 1.62; 95% CI: 1.10-2.39; p = 0.015) and history of Type I hypersensitivity reactions (hazard ratio: 1.48; 95% CI: 1.02-2.14; p = 0.037) were significantly associated with the development of irAEs. High serum albumin levels and history of Type I hypersensitivity reactions are risk factors for irAEs.

KW - Fine-Gray regression model

KW - PD-1

KW - Type I hypersensitivity reaction

KW - immune checkpoint inhibitors

KW - immune-related adverse events

KW - risk factor

UR - http://www.scopus.com/inward/record.url?scp=85108124033&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85108124033&partnerID=8YFLogxK

U2 - 10.2217/fon-2020-0861

DO - 10.2217/fon-2020-0861

M3 - Article

C2 - 33878916

AN - SCOPUS:85108124033

SN - 1479-6694

VL - 17

SP - 2593

EP - 2603

JO - Future Oncology

JF - Future Oncology

IS - 20

ER -

Analysis of risk factors for immune-related adverse events in various solid tumors using real-world data

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this